Abstract | AIM: METHODS: Intravitreal bevacizumab (1 mg) was injected into eight eyes of eight patients with mCNV in this non-randomised, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fluorescein angiography findings were examined before and after treatment. The minimum follow-up time was 3 months. RESULTS: The mean BCVA was 0.26 before treatment and 0.51 at the last visit (p = 0.009). The BCVA improved to two or more lines in six eyes (75%) and remained the same in two eyes (25%). Leakage from the mCNV on fluorescein angiography decreased in seven eyes (87.5%). The choroidal neovascularisation area on fluorescein angiography (p = 0.049) and the foveal thickness on OCT images decreased significantly (p = 0.027) after the treatment. No major complications developed. CONCLUSION:
|
Authors | H Sakaguchi, Y Ikuno, F Gomi, M Kamei, M Sawa, M Tsujikawa, Y Oshima, S Kusaka, Y Tano |
Journal | The British journal of ophthalmology
(Br J Ophthalmol)
Vol. 91
Issue 2
Pg. 161-5
(Feb 2007)
ISSN: 0007-1161 [Print] England |
PMID | 16914470
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Adult
- Aged
- Angiogenesis Inhibitors
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Choroidal Neovascularization
(drug therapy, etiology, pathology, physiopathology)
- Female
- Follow-Up Studies
- Fovea Centralis
(pathology)
- Humans
- Male
- Middle Aged
- Myopia, Degenerative
(complications)
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(drug effects)
|